UCLA Health continues northward march
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Biotech’s movers and shakers gather for BioMedley
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Scenes from the reopening: lottery winners, maskless customers
The doors of the region’s businesses were fully open on June 15 for the first time in 15 months — and two Central Coast residents became millionaires — as California lifted nearly all of its COVID-19 restrictions. The state appears to have the upper hand on the virus, with new cases down to around 1,000 Read More →
Sientra closes sale of miraDry at $10M loss
Sientra, a Goleta-based plastic surgery device company specializing in breast implants, announced June 11 that it had closed the sale of miraDry, a non-surgical dermatological treatment. The $10 million sale brought half of what Sientra paid for the business four years ago. The miraDry system is an FDA-approved treatment to reduce underarm sweat, hair and Read More →
Amgen’s new drug could be a blockbuster
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Our View: We’ll all be winners if a lottery ups vaccine rates
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen reaches billion-dollar licensing deal with Japanese firm
Amgen announced an agreement June 1 with Kyowa Kirin, a Japanese pharmaceutical company, to jointly develop and commercialize a human monoclonal antibody that Kyowa Kirin is developing to treat atopic dermatitis and other autoimmune diseases. The deal could be worth $1.25 billion or more. Amgen will led the development, manufacturing and commercialization for the treatment, Read More →
